Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotavirus RV3 Vaccine in Neonates
NCT04185545Phase 3Completed
- Sponsor
- Bio Farma
- Start
- Oct 2020
- Primary completion
- Apr 2022
- Modality
- Live Attenuated Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of RV3-BB in rotavirus gastroenteritis (6 arms), sponsored by Bio Farma. Primary endpoint: Efficacy against severe acute rotavirus gastroenteritis. Started Oct 2020; status: completed.
02
Drugs
RV3-BB
03
Conditions
rotavirus gastroenteritis
Beyond the preview
Go deeper on NCT04185545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185545.